Business
Immunovant Announces Pricing of $550 Million Common Stock Financing
Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Immunovant Inc.","displaySize":"","headline":null,"caption":"Immunovant Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PQ86vzFPuLGg8eDjozRmNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTU4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006","width":200,"height":32}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Funding to provide runway through potential Graves’ Disease commercial launch","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":77,"olType":false},{"type":"text","content":"NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company’s controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.","length":628,"tagName":"p"},{"type":"text","content":"Immunovant currently expects that its existing cash and cash equivalents, together with the proceeds from the transaction, will be sufficient to fund its operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in the Graves’ Disease indication.","length":285,"tagName":"p"},{"type":"text","content":"Immunovant offered 26.2 million shares of its common stock in the offering at an offering price of $21.00 per share. The offering is expected to close on or about December 12, 2025, subject to satisfaction of customary closing conditions.","length":238,"tagName":"p"},{"type":"text","content":"Leerink Partners is acting as the sole underwriter for the offering.","length":68,"tagName":"p"},{"type":"text","content":"The shares in the offering are being offered by Immunovant pursuant to an automatic registration statement on Form S-3 previously filed with the SEC.","length":149,"tagName":"p"}...